ABSTRACT
Objective To estimate the range of the age- and sex-specific infection fatality risk (IFR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on confirmed coronavirus disease 2019 (COVID-19) deaths and excess all-cause deaths.
Design Nationwide population-based seroepidemiological study combined with two national surveillance systems.
Setting and participants Non-institutionalized Spanish population of all ages.
Main outcome measures The range of IFR was calculated as the observed number of COVID-19 deaths and excess deaths divided by the estimated number of SARS-CoV-2 infections in the non-institutionalized Spanish population. Laboratory-confirmed COVID-19 deaths were obtained from the National Epidemiological Surveillance Network (RENAVE) and excess all-cause deaths from the Monitoring Mortality System (MoMo) up to July 15, 2020. SARS-CoV-2 infections were derived from the estimated seroprevalence by a chemiluminiscent microparticle immunoassay for IgG antibodies in 61,092 participants in the ENE-COVID nationwide serosurvey between April 27 and June 22, 2020.
Results The overall IFR (95% confidence interval) was 0.8% (0.8% to 0.9%) for confirmed COVID-19 deaths and 1.1% (1.0% to 1.2%) for excess deaths. The IFR ranged between 1.1% (1.0% to 1.2%) and 1.4% (1.3% to 1.5%) in men and between 0.6% (0.5% to 0.6%) and 0.8% (0.7% to 0.8%) in women. The IFR increased sharply after age 50, ranging between 11.6% (8.1% to 16.5%) and 16.4% (11.4% to 23.2%) in men ≥80 years and between 4.6% (3.4% to 6.3%) and 6.5% (4.7% to 8.8%) in women ≥80 years.
Conclusion The sharp increase in SARS-CoV-2 IFR after age 50 was more marked in men than in women. Fatality from COVID-19 is substantially greater than that reported for other common respiratory diseases such as seasonal influenza.
WHAT IS ALREADY KNOWN ON THIS TOPIC Infection fatality risk (IFR) for SARS-CoV-2 is a key indicator for policy decision making, but its magnitude remains under debate. Case fatality risk, which accounts for deaths among confirmed COVID-19 cases, overestimates SARS-CoV-2 fatality as it excludes a large proportion of asymptomatic and mild-symptomatic infections. Population-based seroepidemiological studies are a valuable tool to properly estimate the number of infected individuals, regardless of symptoms. Also, because ascertainment of deaths due to COVID-19 is often incomplete, the calculation of the IFR should be complemented with data on excess all-cause mortality. In addition, data on age- and sex-specific IFR are scarce, even though age and sex are well known modifiers of the clinical evolution of COVID-19.
WHAT THIS STUDY ADDS Using the ENE-COVID nationwide serosurvey and two national surveillance systems in Spain, this study provides a range of age- and sex-specific IFR estimates for SARS-CoV-2 based on laboratory-confirmed COVID-19 deaths and excess all-cause deaths. The risk of death was very low among infected individuals younger than 50 years, but it increased sharply with age, particularly among men. In the oldest age group (≥80 years), it was estimated that 12% to 16% of infected men and 5% to 6% of infected women died during the first epidemic wave.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ENE-COVID study was funded by Spanish Ministry of Health, Institute of Health Carlos III & Spanish National Health System.No other external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the Institute of Health Carlos III (Register number: PI 39_2020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors
↵† Joint senior authors
↵‡ ENE-COVID Collaborators are listed in the supplementary material
Roberto Pastor-Barriuso: rpastor{at}isciii.es
Beatriz Pérez-Gómez: bperez{at}isciii.es
Miguel A Hernán: mhernan{at}hsph.harvard.edu
Mayte Pérez-Olmeda: mayteperez{at}isciii.es
Raquel Yotti: raquel.yotti{at}isciii.es
Jesús Oteo-Iglesias: joteo{at}isciii.es
Jose L Sanmartín: jsanmartin{at}mscbs.es
Inmaculada León-Gómez: ileon{at}isciii.es
Aurora Fernández-García: aurorafg{at}isciii.es
Pablo Fernández-Navarro: pfernandezn{at}isciii.es
Israel Cruz: cruzi{at}isciii.es
Mariano Martín: mmartingarc{at}externos.mscbs.es
Concha Delgado-Sanz: cdelgado{at}isciii.es
Nerea Fernández de Larrea: nfernandez{at}isciii.es
Jose León Paniagua: jpaniagua{at}isciii.es
Juan F Muñoz-Montalvo: jfmunoz{at}mscbs.es
Faustino Blanco: fblancog{at}mscbs.es
Amparo Larrauri: alarrauri{at}isciii.es
Marina Pollán: mpollan{at}isciii.es
A sensitivity analysis has been added to correct IFR figures for imperfect sensitivity and specificity of the serological assay. Bivaried meta-analysis of reported sensitivity and specificity in 23 diagnostic accuracy studies of the Abbott ARCHITECT SARS-CoV-2 IgG used in ENE-COVID study. A supplementary figure representing the first COVID-19 epidemic wave in Spain.
Data Availability
The manuscript includes all figures needed to replicate the IFR estimations and indicate the sources used. ENE-COVID seroprevalence figures are provided here for all sex and age groups. Data on deaths come from RENAVE and MoMo, two Spanish National Surveillance Systems. Anonymized data from these systems are available under request. The specific formulary for this purpose is provided by the Department of Communicable Diseases at the National Center for Epidemiology. Instituto de Salud Carlos III. C/ Monforte de Lemos 5 28029 Madrid. (e-mail: vigilancia.cne{at}isciii.es and mortalidad{at}isciii.es respectively). Population figures have been provided by the National Institute of Statistics and are publicly available at their website (www.ine.es).
https://portalcne.isciii.es/enecovid19/
https://momo.isciii.es/public/momo/dashboard/momo_dashboard.html
